Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

of NKTR-118 as a Selective Oral Peripheral Opioid Antagonist"

Poster #28: "NKTR-118 (oral PEG-naloxol), a PEGylated Derivative of Naloxone; Demonstration of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models"

Nektar PEGylation Platform

Nektar PEGylation technology can enhance the properties of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It can also be used to modify pharmaceutical agents to preferentially target certain systems within the body. It is a technique in which non-toxic polyethylene glycol (PEG) polymers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs.

Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar is also developing its own product candidates by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of the company's PEGylation technology platform and NKTR-118. These forward-looking statements involve important risks and uncertainties, includ
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is pleased ... of the first-of-its-kind comic book available in Canada ... been designed specifically to educate children and their parents about ... affecting more than 300,000 Canadians. Eisai is guided ... (hhc) , in which the patient is central – there ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... Aug. 21, 2014  Seventy-one percent of Americans believe the ... a serious public health and safety issue in ... survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse problem ... this very serious health situation facing our country," Rex ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... thinking about cosmetic surgery, your first stop should be at ...   SculptMyDream.com is the first website to let individuals ... photography.  Not only will this help you "Sculpt YOUR dream", ... that dream into reality. (Photo:   http://photos.prnewswire.com/prnh/20110720/NY38494 ...
... 20, 2011 Landacorp , A Carewise Health ... solutions, today announced that its CareRadius Suite has been ... Coventry Health Care is a diversified national ... plans that serve more than five million members across ...
Cached Medicine Technology:See the Results of Your Breast Augmentation, Before Surgery 2Coventry Health Care Selects Landacorp's CareRadius Suite to Advance Collaborative Care 2
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... is an internationally well-known supplier and leader in the ... collection of elegant bamboo floorings . These new ... for high quality floorings for their own houses. Now, ... to 29 percent off). Before the end of August, ... The company’s bamboo flooring products are made using unique, ...
(Date:8/21/2014)... Mich. Using heart-lung support technology, the University of ... of kidneys, livers and pancreases available for transplant by ... the journal Transplantation and detail the impact ... Oxygenation, or ECMO, to improve the quality and viability ... "Organ transplant is limited by the number of donated ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
Breaking Medicine News(10 mins):Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2
... , , HATBORO, Pa., Aug. 13 InfoLogix, Inc. ... solutions for the healthcare and commercial industries, today announced financial results for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090618/NE3513 5 LOGO ... , , David T. Gulian, president and chief ...
... , , , BRISTOL, ... KG ) today announced that the U.S. Food and Drug ... Extended Release Capsules for oral use, a long-acting Schedule II ... when a continuous, around-the-clock opioid analgesic is needed for an ...
... , , REDWOOD ... ) today reported financial results and corporate progress for its fiscal ... , "With a slower than expected rate of ... quarter we had to make difficult decisions to revise our direct ...
... , , IRVINE, Calif., ... of surgical products used in the treatment of patients suffering from ... June 30, 2009. , , Net revenues in ... the prior year second quarter net revenues of $4,119,000. The ...
... rise if organ comes from deceased man, study finds, , ... donated organ came from a deceased male face an increased ... Canadian researchers have found. , The risk is short-term, though, ... researchers said. Their study found that the risk goes ...
... Genetic mutation could explain why some function fine on six hours ... few can get by just fine on six hours of sleep, ... why. , The finding doesn,t appear likely to help people with ... people sleep as long as they do, said study co-author Ying-Hui ...
Cached Medicine News:Health News:InfoLogix Announces Second Quarter Financial Results 2Health News:InfoLogix Announces Second Quarter Financial Results 3Health News:InfoLogix Announces Second Quarter Financial Results 4Health News:InfoLogix Announces Second Quarter Financial Results 5Health News:InfoLogix Announces Second Quarter Financial Results 6Health News:InfoLogix Announces Second Quarter Financial Results 7Health News:InfoLogix Announces Second Quarter Financial Results 8Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 2Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 3Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 4Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 5Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 6Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 2Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 3Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 4Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 5Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 6Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 8Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 9Health News:Cardiogenesis Reports Second Quarter 2009 Results 2Health News:Cardiogenesis Reports Second Quarter 2009 Results 3Health News:Cardiogenesis Reports Second Quarter 2009 Results 4Health News:Cardiogenesis Reports Second Quarter 2009 Results 5Health News:Cardiogenesis Reports Second Quarter 2009 Results 6Health News:Cardiogenesis Reports Second Quarter 2009 Results 7Health News:Kidney Donor's Sex Could Affect Women's Outcomes 2Health News:They Snooze Less, But They Don't Lose 2
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... AlphaCor is a biocompatible, flexible, one-piece artificial ... or diseased native cornea., ,The World Health ... more than 10 million people worldwide, however ... year. This shortfall is due to a ...
PDA-version of the complete ICD-9 diagnosis codes....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
Medicine Products: